Payer Coverage in Polycythemia VeraVideo Categories: Polycythemia Vera
Supported through funding from Incyte
Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy.
David S. Siegel, MD, PhD, at the John Theurer Cancer Center in Hackensack, NJ, explains the benefits of worldwide clinical trials in creating more consistent, less toxic treatment options for multiple myeloma. New drugs are coming along, and the clinical trials for those drugs are beginning to mature.